×
戻る Agenda
Looking Closer into the Utility of Adaptive Approaches
Session Chair(s)
Sue-Jane Wang, PHD, MA, MS
Mathematician Statistician
FDA, United States
Optimal Choice of the Type I Error Rate in Drug Development
Learning Objective : Describe the randomization procedure; Discuss popular adaptive dose designs; Explain statistical principles in drug development.
Speaker(s)
Optimal Choice of the Type I Error Rate in Drug Development
Raina Duan, PHD
Aptiv Solutions, United States
Gaining Information under Ethical/Cost Constraints in Dose Finding Studies
Valerii Fedorov, DRSC
Quintiles Transnational Corp, United States
Vice President, Predictive Analytics, Innovation
A Hybrid Randomization Algorithm Offering the Best of Minimization, Dynamic and Permuted Block Randomization Methods
Jonathan (Yoni) D Lebowitsch
Medidata Solutions Worldwide, United States
Product Manager